Correll CK, et al. - Researchers conducted this retrospective, observational case series study to describe the clinical characteristics of childhood-onset lupus erythematosus panniculitis (LEP) and report on the use of rituximab in treatment-refractory childhood-onset LEP. The sample consisted of 4 childhood-onset LEP patients (3 male; mean [SD] age at treatment, 15 [5.9] years) who were treated with rituximab in a single-center, tertiary care clinic with pediatric dermatology and pediatric rheumatology clinics between July 1, 2014, and July 1, 2018. According to findings, LEP is a rare and disfiguring skin disease in childhood without standard criterion therapies but the findings from this case series suggest that rituximab can be an effective and well-tolerated treatment.